

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Mega Genomics Limited**

**美因基因有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 6667)**

## **DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Mega Genomics Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Tuesday, 30 August 2022 for the purpose of considering and approving the interim results of the Group for the six month ended 30 June 2022 and its publication, the payment of an interim dividend, if any, and transacting any other business.

By Order of the Board  
**Mega Genomics Limited**  
**LIN Lin**

*Executive Director and Chairperson*

Hong Kong, 18 August 2022

*As at the date of this announcement, the Board comprises Dr. Yu Rong, Ms. Lin Lin, Mr. Huang Yufeng and Ms. Jiang Jing as executive Directors; Ms. Guo Meiling as non-executive Director; and Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan as independent non-executive Directors.*

\* For identification purpose only